TABLE 2.
Cabozantinib treatment details
| RCC patients (n = 25) | SGC patients (n = 22) | |
|---|---|---|
| Dose at start of treatment | ||
| 60 | 8 (32) | 22 (100) |
| 40 | 13 (52) | 0 |
| 20 | 4 (16) | 0 |
| Median treatment duration (weeks) | 22 (4‐151) | 29.5 (3‐55) |
| Dose reduction during treatment | 15 (60) | 20 (91) |
| Reason of treatment discontinuation | 21 (84) a | 22 (100) |
| Toxicity | 5 (20) | 3 (14) |
| Progressive disease | 16 (64) | 6 (27) |
| Death | 0 | 0 |
| Other b | 0 | 13 (59) |
| Best tolerated cabozantinib dose (mg) | ||
| 20 | 5 (20) | 11 (50) |
| 27 c | 1 (4) | 0 |
| 30 c | 3 (12) | 2 (9) |
| 40 | 13 (52) | 7 (32) |
| 50 c | 1 (4) | 0 |
| 60 | 2 (8) | 2 (9) |
| Median average dose intensity (mg) | 39 (20‐60) | 38 (24‐60) |
| Total number of samples at steady state | 42 | 37 |
| Median number of samples per patient | 1 (1‐5) | 1 (1‐3) |
a
Four patients still on treatment at data cut‐off.
b
Stop of study due to safety concerns.
c
Cabozantinib dose reached via an alternative dosing schedule (eg, 20 and 40 mg used alternately).